Wang DD - Search Results

1

Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trials.

Wang DD, Zhang S, Zhao H, Men AY, Parivar K. Wang DD, et al. J Clin Pharmacol. 2009 Sep;49(9):1012-24. doi: 10.1177/0091270009337512. Epub 2009 Jul 20. J Clin Pharmacol. 2009. PMID: 19620385

2

Fixed dosing versus body size-based dosing of therapeutic peptides and proteins in adults.

Zhang S, Shi R, Li C, Parivar K, Wang DD. Zhang S, et al. Among authors: wang dd. J Clin Pharmacol. 2012 Jan;52(1):18-28. doi: 10.1177/0091270010388648. Epub 2011 Jan 13. J Clin Pharmacol. 2012. PMID: 21233304

3

Standardized visual predictive check versus visual predictive check for model evaluation.

Wang DD, Zhang S. Wang DD, et al. J Clin Pharmacol. 2012 Jan;52(1):39-54. doi: 10.1177/0091270010390040. Epub 2011 Jan 21. J Clin Pharmacol. 2012. PMID: 21257797

4

Utility of population pharmacokinetic modeling in the assessment of therapeutic protein-drug interactions.

Chow AT, Earp JC, Gupta M, Hanley W, Hu C, Wang DD, Zajic S, Zhu M; Population PK TPDI Working Group. Chow AT, et al. Among authors: wang dd. J Clin Pharmacol. 2014 May;54(5):593-601. doi: 10.1002/jcph.240. Epub 2013 Dec 6. J Clin Pharmacol. 2014. PMID: 24272952

5

PARP activity in peripheral blood lymphocytes as a predictive biomarker for PARP inhibition in tumor tissues - A population pharmacokinetic/pharmacodynamic analysis of rucaparib.

Wang DD, Li C, Sun W, Zhang S, Shalinsky DR, Kern KA, Curtin NJ, Sam WJ, Kirkpatrick TR, Plummer R. Wang DD, et al. Clin Pharmacol Drug Dev. 2015 Mar;4(2):89-98. doi: 10.1002/cpdd.176. Epub 2015 Jan 26. Clin Pharmacol Drug Dev. 2015. PMID: 27128213 Clinical Trial.

6

Physiologically Based Pharmacokinetic Modeling of Palbociclib.

Yu Y, Loi CM, Hoffman J, Wang D. Yu Y, et al. J Clin Pharmacol. 2017 Feb;57(2):173-184. doi: 10.1002/jcph.792. Epub 2016 Aug 22. J Clin Pharmacol. 2017. PMID: 27402157 Clinical Trial.

7

Characterization of Neutropenia in Advanced Cancer Patients Following Palbociclib Treatment Using a Population Pharmacokinetic-Pharmacodynamic Modeling and Simulation Approach.

Sun W, O'Dwyer PJ, Finn RS, Ruiz-Garcia A, Shapiro GI, Schwartz GK, DeMichele A, Wang D. Sun W, et al. J Clin Pharmacol. 2017 Sep;57(9):1159-1173. doi: 10.1002/jcph.902. Epub 2017 Apr 18. J Clin Pharmacol. 2017. PMID: 28419480 Clinical Trial.

8

Impact of Acid-Reducing Agents on the Pharmacokinetics of Palbociclib, a Weak Base With pH-Dependent Solubility, With Different Food Intake Conditions.

Sun W, Klamerus KJ, Yuhas LM, Pawlak S, Plotka A, O'Gorman M, Kirkovsky L, Kosa M, Wang D. Sun W, et al. Clin Pharmacol Drug Dev. 2017 Nov;6(6):614-626. doi: 10.1002/cpdd.356. Epub 2017 Apr 21. Clin Pharmacol Drug Dev. 2017. PMID: 28430398 Clinical Trial.

9

The Utility of a Population Approach in Drug-Drug Interaction Assessments: A Simulation Evaluation.

Wang DD, Yu Y, Kassir N, Zhu M, Hanley WD, Earp JC, Chow AT, Gupta M, Hu C. Wang DD, et al. J Clin Pharmacol. 2017 Oct;57(10):1268-1278. doi: 10.1002/jcph.921. Epub 2017 May 17. J Clin Pharmacol. 2017. PMID: 28513856

10

Predicting Overall Survival and Progression-Free Survival Using Tumor Dynamics in Advanced Breast Cancer Patients.

Lim HS, Sun W, Parivar K, Wang D. Lim HS, et al. AAPS J. 2019 Jan 30;21(2):22. doi: 10.1208/s12248-018-0290-x. AAPS J. 2019. PMID: 30701431

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,335 results

Search Page

Filters